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Abstract
HBsAg-negative/HBcAb-positive haematopoietic stem cell transplant (HSCT) recipients are at high risk of hepatitis B virus (HBV)
reactivation. Allogeneic HSCT recipients from years 2000 to 2010 were evaluated in order to study the impact of being HBsAg-negative/
HBcAb-positive in this population. Overall, 137 of 764 patients (18%) were HBsAg-negative/HBcAb-positive before HSCT. Overall survival,
non-relapse mortality (NRM), acute and chronic graft-vs.-host disease were similar in HBcAb-positive and HBcAb-negative patients.
Reactivation occurred in 14 patients (10%) within a median of 19 months after HSCT (range 9–77). Cause-speciﬁc hazard for reactivation
was decreased in the case of an HBV-immune/exposed donor (HRadjusted = 0.12; 95% CI, 0.02–0.96; p 0.045) and increased in patients who
received rituximab treatment (HRadjusted = 2.91; 95%CI, 0.77–10.97; p 0.11). Competing risk analyses documented a protective role of an
HBV-immune/exposed donor (p 0.041) and an increased probability associated with the length of treatment with cyclosporine (p <0.001)
and treatment with rituximab (but not with low-dose rituximab prophylaxis, p <0.001 at each landmark point). No differences in overall
survival and NRM were found between patients with and without HBV reactivation. The donor’s immunity was independently and
consistently associated with a decreased risk of HBV reactivation, while rituximab and cyclosporine treatments increased the probability.
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Introduction
Hepatitis B reactivation can occur years after HBsAg loss, due
to the ability of the hepatitis B virus (HBV) to remain latent in
the liver as covalently closed circular DNA [1]. In immuno-
compromised patients, reactivation in both inactive HBsAg
carriers and in those with an occult infection can lead to
chronic or fulminant hepatitis B [2]. Haematopoietic stem cell
transplant (HSCT) recipients are at particularly high risk of
reactivation because of long and profound immunosuppres-
sion. The data on the rate of reactivation in HBsAg-negative
and HBcAb-positive (HBsAg/HBcAb+) HSCT recipients and
on risk factors are limited because of a small number of
patients included in the previous observational studies [3–13].
The reported reactivation rate varied from 6% to 54% [3–13].
Although some risk factors for HBV reactivation have been
described, their impact should be evaluated with appropriate
statistical analyses in the context of the presence of numerous
other clinical conditions that inﬂuence the outcome in this
population.
The aims of this study were to identify HBV reactivation
rate, its risk factors and outcome and to analyse whether being
HBsAg/HBcAb+ could negatively affect the transplant out-
come.
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Materials and Methods
Patients and data collection
All patients who underwent allogeneic HSCT between 1
January 2000 and 31 December 2010 at San Martino University
Hospital in Genoa were evaluated. Retrospective data were
obtained from a prospectively collected database and inte-
grated with chart reviews. Patients without available HBV
serology at transplant were excluded. Due to the retrospec-
tive nature of the study a speciﬁc informed consent was not
required from patients; however, all of them gave consent for
data collection in the medical records they signed at transplant.
Baseline and outcome data were recorded. Baseline char-
acteristics included demographic variables (age, sex), dis-
ease-related variables (type and phase of the underlying
disease), transplant-related variables (type of donor, condi-
tioning regimen, graft-vs.-host disease (GvHD) prophylaxis)
and donor’s and recipient’s HBV serostatus. The following
outcome variables were recorded: GvHD (its grade and
treatment), relapse, rituximab administration and survival,
both overall and disease-free, the latter expressed as
non-relapse mortality (NRM). For HBsAg/HBcAb+ patients,
post-transplant levels of liver enzyme tests were analysed in
order to identify any episode of hepatitis. For patients with
HBV reactivation, data concerning diagnosis of reactivation,
antiviral treatment and outcome were collected.
Transplant-related procedures
Transplantation was performed according to institutional
protocols as previously described [14–16]. Since 2005, low-
dose rituximab (200 mg/m2) was administered on day 5 after
HSCT as prophylaxis against post-transplant lymphoprolifera-
tive disease (PTLD) in patients receiving grafts from donors
who were not matched related [17].
Post-transplant HBV testing was performed if clinically
indicated or, in asymptomatic patients, at the discretion of the
attending physician. Serum detection of HBV-DNA was
performed with different assays available at the time of
transplant (data are not shown).
Deﬁnitions
Hepatitis B virus reactivation was deﬁned as reappearance of
HBsAg, with or without increased liver enzymes. Diagnosis
and clinical grading of acute and chronic GvHD (aGvHD and
cGvHD) were performed according to established criteria
[15]. Rituximab treatment was deﬁned as administration of at
least one full dose (350 mg/m2) for treatment of either PTLD
or a relapsed haematological disorder. Single low-dose ritux-
imab administration (see Transplant-related procedures) was
considered as prophylaxis.
Statistical analysis
The ﬁrst analysis focused on the impact of being HBsAg/
HBcAb+ on outcome endpoints such as overall survival, NRM,
aGvHD and cGvHD compared with HBsAg/HBcAb
patients. The chi-squared test (or Fisher’s exact test when
applicable) and Student’s t-test were applied for, respectively,
categorical and continuous variables. GvHD, relapse of
underlying disease and survival were considered as
time-dependent variables. The Cox model was applied to
assess the impact on cause-speciﬁc hazard. The Fine and Gray
model was used to assess impact on cumulative incidence [18],
considering relapse and death without GvHD as competing
events for NRM and GvHD, respectively. Variables signiﬁcantly
different between HBcAb+ and HBcAb patients were added
into the ﬁnal multivariate model with a stepwise procedure
after having veriﬁed that they were singularly associated with
outcomes.
The second analysis included only HBcAb+ patients and
compared those with and without reactivation. Univariate
analysis was performed as described above. Additionally, the
follow-up and the lengths of cyclosporine and steroid treat-
ments were considered as continuous variables and compared
with non-parametric Mann–Whitney test. The impact of
time-ﬁxed and time-dependent variables on cause-speciﬁc
hazards for reactivation was initially assessed in the classical
Cox regression model. Subsequently, the Fine and Gray model
for competing risks was used to assess the direct effect of the
time-ﬁxed characteristics on the cumulative incidence of
reactivation, with death in the absence of reactivation consid-
ered as a competing event [18]. Time-dependent variables
were assessed in a landmark analysis at different landmark
points (1, 2, 3, 4, 6, 12 and 18 months after HSCT) [19,20],
and their effects, considered as time-ﬁxed on cumulative
incidence of reactivation, were assessed with the Fine and
Gray model [18]. Patients who were not at risk any more (due
to death or HBV reactivation already present) at each
landmark point were not considered for respective analyses.
Cumulative incidence of reactivation in the presence of
competing risks was calculated [21,22].
Finally, Cox regression was used to assess differences in
overall survival and NRM between patients with and without
reactivation, with reactivation status considered as a
time-dependent variable. To verify the effect of the length of
follow-up on the association between the length of immuno-
suppressive treatment with steroids or cyclosporine and HBV
reactivation, the ANCOVA (analysis of covariance) model was
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used. For length of treatment with steroids, cube root
transformation of values was used to normalize its distribution.
Hazard ratios (HRs) and sub-hazard ratios (SHRs) with
relative 95% conﬁdence interval (CI) were reported for
Cox-regression and Fine and Gray analyses, respectively. A
p-value of <0.05 was considered statistically signiﬁcant. Stata
(version 11.0; Stata Corp., College Station, TX, USA) was used
for computation.
Results
Patients’ characteristics
During the study period 851 patients received allogeneic HSCT;
87 (10%) of them were excluded because of unknown HBV
status. Among the remaining 764 patients, 147 (18%) were
HBcAb+ at HSCT. Ten (1.3%) were also HBsAg+, thus 754
HBsAg patients were included in the study (Table 1). Among
137 HBsAg/HBcAb+ recipients, 124 were also HBsAb+, and
the donors’ HBV immunity was as follows: 99 HBV na€ıve, 22
HBcAb+, 13 vaccinated (only HBsAb+) and three HBsAg+ but
HBV-DNAnegative.All recipientswereHIV-seronegative,while
14 (1.8%; six of them HBV exposed) were positive for HCV.
Comparison of outcomes in HBcAb+ and HBcAb patients
Median follow-up for HBcAb+ and HBcAb patients was,
respectively, 12 (range, 0–145) and 20 months (range, 0–138);
p 0.26. At the last follow-up, 347 (45%) patients were alive:
47% in the HBcAb group and 40% in HBcAb+ group
(Table 1). Overall survival did not differ between the two
groups, even after adjustment for both factors signiﬁcantly
different between the groups and for variables associated with
overall survival (HRadjusted = 1.16, 95% CI 0.91–1.49, p 0.23).
No difference in NRM or aGvHD was found, considering both
impact on cause-speciﬁc hazard and on cumulative incidence,
also after adjusting for factors found to be different between
the two groups and for those associated with NRM or aGvHD
(HRadjusted = 0.84, 95% CI 0.43–1.67, p 0.63, and
HRadjusted = 1.55, 95% CI 0.79–3.05, p 0.21, respectively, for
NRM and acute GvHD grade III-IV).
Regarding cGvHD, a higher risk of limited cGvHD was
observed in HBcAb+ patients, although the difference was not
statistically signiﬁcant. However, when considering the impact
on cumulative incidence with death without cGvHD as a
competing event, no signiﬁcant differences between the two
groups were found, both in limited and in extensive cGvHD
(for limited cGVHD, HRadjusted = 1.36, 95% CI 0.97–1.90,
p 0.075; SHRadjusted = 1.11, 95% CI 0.79–1.55, p 0.54; for
extensive cGVHD, HRadjusted = 1.32, 95% CI 0.87–2.02,
p 0.20; SHRadjusted = 1.05, 95% CI 0.69–1.61, p 0.81).
Incidence of HBV reactivation
Overall, 14 patients experienced HBV reactivation (10.2%) at a
median time of 19 months after HSCT (range, 9–77). Cumu-
lative incidence of reactivation was 6.3% (95% CI 2.9–11.3) at
2 years, 8.7% (95% CI 4.6–14.5) at 3 years, 9.6% (95% CI 5.3–
15.5) at 5 years and 12.2% (95% CI 6.9–19.1) at 7 years.
TABLE 1. Baseline and post-transplant characteristics of all
754 patients, divided into HBV exposed and not
Characteristics
HBsAg/
HBcAb
n = 617 (%)
HBsAg/
HBcAb+
n = 137 (%) p
Baseline
Sex, male 371 (60) 84 (61) 0.85
Median age, years
(range)
40 (9–71) 45 (16–69) 0.007
Donor HBV-immune/
exposeda
59/302 (20) 38/123 (31) 0.016
Type of disease
Acute leukaemia 305 (49) 77 (56) 0.083
Chronic
myeloproliferative
disease
122 (20) 17 (12)
Chronic
lymphoproliferative
disease
90 (15) 19 (14)
Myelodysplastic
syndrome
59 (10) 9 (7)
Severe aplastic
anaemia
41 (6) 15 (11)
Donor
Matched related 261 (42) 76 (55) 0.005b
Matched unrelated 165 (27) 24 (18)
Mismatched related 56 (9) 18 (13)
Mismatched unrelated 39 (6) 5 (4)
Cord blood 83 (14) 12 (9)
Haploidentical 13 (2) 2 (1)
Disease phase at transplant
First complete remission 215 (35) 52 (38) 0.68
Second or following
remission
174 (28) 34 (25)
Active disease 228 (37) 51 (37)
Conditioning regimen
Myeloablative 364 (59) 63 (46) 0.005
Reduced intensity 253 (41) 74 (54)
ATG
No 287 (46) 79 (58) 0.036c
≤7.5 mg 226 (37) 44 (32)
>7.5 mg 104 (17) 14 (10)
GvHD prophylaxis
CsA + MTX
standard dose
135 (22) 20 (15) 0.067
CsA + MTX
low dose
380 (62) 101 (74)
CsA + MMF 89 (14) 14 (10)
CsA + MMF +
cyclophosphamide
13 (2) 2 (1)
Post-transplant
Acute GvHDd
Absent 143 (23) 29 (21)
Grade I 306 (50) 60 (44)
Grade II 135 (22) 36 (26)
Grade III and IV 33 (5) 12 (9)
Chronic GvHD
Absent 281 (45) 62 (45)
Limited 209 (34) 47 (35)
Extensive 127 (21) 28 (20)
Clinical relapse, yes 162 (26) 34 (25) 0.44d
Overall survival
Alive 292 (47) 55 (40)
Dead 325 (53) 82 (60)
ATG, antithymocyte globulin; CsA, cyclosporine A; GvHD, graft vs. host disease;
MMF, mycophenolate mofetil; MTX, methotrexate.
aData available for 425 patients.
bFor matched related vs. other donors.
cFor any dose of ATG vs. no ATG.
dp value obtained with the Fine and Gray model for competing risk.
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Among HBcAb-positive patients who were alive at 1, 3, 5 and
7 years after HSCT, 2% (2/86), 13% (11/62), 21% (12/56) and
26% (14/54) developed HBV reactivation, respectively.
Among HBcAb+ patients without a documented reactiva-
tion, 41 had a signiﬁcant rise in alanine aminotransferase (ALT).
In two of them no likely cause of ALT increase was identiﬁed,
thus an HBV reactivation could not be excluded.
Clinical characteristics of HBV reactivation
Clinical characteristics of 14 patients with HBV reactivation
are shown in Appendix 1. No patient experienced fulminant
hepatitis. One patient had reactivated HBV while receiving
lamivudine prophylaxis, but his compliance was suboptimal.
Characteristics of patients who did and did not experience
HBV reactivation are shown in Table 2. All but one of the
donors of HBV-reactivated patients were HBsAg/HBsAb/
HBcAb, while one was vaccinated. As no difference in
reactivation rate was observed among donors who were
vaccinated or naturally exposed to HBV (respectively, 1/13 and
0/25 reactivation cases), they were grouped together for the
analyses of risk factors (Table 2).
The median follow-up was signiﬁcantly longer in patients
with HBV reactivation, compared with those who did not
reactivate (84 months, range 12–145, vs. 12 months, range 0–
131; p <0.01).
Risk factors for reactivation
Results of univariate and multivariate analyses of the risk of
HBV reactivation, both cause-speciﬁc and cumulative inci-
dence, are reported in Table 3. The lengths of treatment with
cyclosporine and steroids were signiﬁcantly longer in patients
who experienced reactivation compared with those who did
not (p <0.001 and p 0.036, respectively). However, after
correcting for the length of follow-up, only the length of
treatment with cyclosporine, but not with steroids, remained
signiﬁcantly longer in the reactivation group (p 0.013 and
p 0.14, respectively).
Regarding cause-speciﬁc hazard for reactivation, transplant
from an HBV-immune/exposed donor was associated with a
signiﬁcantly reduced risk (HR = 0.12, 95% CI 0.02–0.89;
p 0.039). No other baseline variable inﬂuenced signiﬁcantly
the risk of reactivation. Considering the impact of time-depen-
dent variables, treatment with rituximab was associated with a
higher risk (HR = 4.5, 95% CI 1.21–16.8; p 0.044). Of note,
none of the patients who received low-dose rituximab as
PTLD prophylaxis developed reactivation, thus HRs for
low-dose rituximab could not be calculated. The multivariate
model conﬁrmed the protective role of an HBV-immune/
exposed donor (HRadjusted = 0.12, 95% CI 0.02–0.96; p 0.045),
while treatment with rituximab did not remain statistically
signiﬁcant (HRadjusted = 2.91, 95% CI 0.77–10.97; p 0.11). The
inﬂuence of donor’s immunity on the risk of HBV reactivation
is shown in Fig. 1.
In the Fine and Gray model, the probability of reactivation
was reduced in cases of HBV-immune/exposed donors and
advanced stages of the underlying disease at HSCT (Table 3).
TABLE 2. Characteristics of HBsAg-negative/HBcAb-posi-
tive patients with and without HBV reactivation
HBV reactivation
No, n = 123 Yes, n = 14
Baseline variables
Gender, male (%) 73 (59) 11 (79)
Median age, years (range) 45 (16–69) 44 (16–61)
Underlying disease
Acute leukaemia 70 (57) 7 (50)
Chronic myeloproliferative disease 16 (13) 1 (7)
Chronic lymphoproliferative disease 17 (14) 2 (14)
Myelodysplastic syndrome 8 (7) 1 (7)
Other 12 (10) 3 (22)
Phase at HSCT
First complete remission 42 (34) 10 (71)
Following complete remission 32 (26) 2 (15)
Active disease 49 (40) 2 (15)
Donor
Matched related 68 (55) 8 (57)
Matched unrelated 22 (18) 2 (14)
Mismatched related 16 (13) 2 (14)
Mismatched unrelated 4 (3) 1 (7)
Cord blood 11 (9) 1 (7)
Haploidentical 2 (2) 0
Donor’s HBV immunitya
HBV natural exposurea 25 (20) 0
HBV vaccination 12 (10) 1 (7)
No exposure 72 (59) 13 (93)
Unknown 14 (11) 0
Recipient’s HBV immunity
HBsAb ≥ 10 UI/mL 75 (61) 9 (64.3)
HBsAb < 10 UI/mL 22 (18) 3 (21.4)
Unknownb 26 (21) 2 (14.3)
Lamivudine prophylaxis, yes 10 (8) 1 (7)
Conditioning regimen
Myeloablative 55 (45) 8 (57)
Reduced intensity 68 (55) 6 (43)
GvHD prophylaxis
Cyclosporine A + methotrexate 18 (14) 2 (14)
Cyclosporine A + methotrexate low dose 91 (74) 10 (72)
Cyclosporine A + MMF 12 (10) 2 (14)
Cyclosporine A + MMF + cyclophosphamide 2 (2) 0
ATG
No 70 (57) 8 (57)
≤7.5 mg 40 (32) 5 (36)
>7.5 mg 13 (11) 1 (7)
Post-transplant variables
Rituximab
No 93 (76) 11 (79)
Low dose as PTLD prophylaxis 15 (12) 0 (0)
High dose as treatment 15 (12) 3 (21)
Acute GvHD
Absent or grade I 79 (64) 10 (71)
Grade II 32 (26) 4 (29)
Grade III-IV 12 (10) 0
Chronic GvHD
Absent 61 (50) 2 (14)
Limited 37 (30) 9 (64)
Extensive 25 (20) 3 (22)
Steroid therapy
<1 mg/kg 56 (46) 4 (29)
≥1 mg/kg 67 (55) 10 (71)
Clinical relapse, yes 41 (33) 3 (21)
Second HSCT, yes 17 (14) 1 (7)
Alive, yes 43 (35) 11 (79)
Non-relapse mortality, yes 42 (34) 1 (71)
CsA, cyclosporine A; GvHD, graft vs. host disease; MMF, mycophenolate mofetil;
MTX, methotrexate; PTLD, post-transplant lymphoproliferative disorder.
aTwenty-two HBcAb-positive, HBsAg-negative; three chronic inactive carriers
(HBsAg-positive, HBV-DNA negative).
bIncluding 26 patients with a positive result without quantitative evaluation.
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The length of treatment with cyclosporine was signiﬁcantly
associated with an increased probability of reactivation (for
1-month increase SHR = 1.03, 95% CI 1.01–1.04; p 0.001).
The results of landmark analysis, reported in Table 3 as
landmark at 6 months, showed that treatment with ritux-
imab was consistently associated with an increased proba-
bility of reactivation, while low-dose rituximab prophylaxis
was not (p <0.001 at all landmark points for 3-group
comparison). At 18 months after transplant rituximab treat-
ment signiﬁcantly increased the risk of reactivation com-
pared with both the no rituximab group and the
rituximab-prophylaxis group (SHR = 7.72, 95% CI 1.30–
45.75; p 0.024).
The multivariate analysis conﬁrmed the protective role of
an HBV-immune/exposed donor (p 0.041), and the increased
probability associated with cyclosporine or rituximab treat-
ment (p <0.001 for both).
Survival of HBcAb-positive patients
Among 137 HBsAg/HBcAb+ patients, 82 died (60%), with a
median survival of 415 days. Survival at 1 year after HSCT was
52.2% (95% CI 43.5–60.2%). Three of 14 patients who
reactivated died. No difference in NRM and overall survival
was observed between patients with and without HBV
reactivation (for NRM, HR = 4.51, 95% CI 0.49–41.93,
p 0.19; for overall survival, HR = 1.68, 95% CI 0.48–5.86,
p 0.42). Also after adjusting for factors found to be different
between the two groups, such as stage of the underlying
disease and HBV-immune/exposed donor, no difference in
overall survival was found (HRadjusted = 1.72; p 0.40).
TABLE 3. Results of univariate and multivariate analyses on cause-speciﬁc and cumulative incidence of HBV reactivation
Variables
Cause speciﬁc Cumulative incidence
HR (95% CI) p-value HRadjusted p-value SHR (95% CI) p-value SHRadjusted p-value
Time-ﬁxed characteristics
Age at transplant (1-year increase) 1.01 (0.96–1.05) 0.78 0.99 (0.95–1.03) 0.62
Gender (female vs. male) 0.38 (0.11–1.37) 0.14 0.42 (0.12–1.48) 0.18
Underlying disease
Acute leukaemia and MDS 1.00 0.81 1.00 0.47
Chronic myelo- or
lymphoproliferative disease
0.72 (0.19–2.72) 0.84 (0.23–3.11)
Other 1.20 (0.32–4.54) 2.04 (0.56–7.47)
Stage of disease
First complete remission 1.00 0.64 1.00 0.049 1.00 0.11
Following complete remission 0.53 (0.12–2.41) 0.30 (0.07–1.33) 0.36 (0.07–1.77)
Active disease 0.69 (0.15–3.16) 0.20 (0.04–0.90) 0.26 (0.07–1.04)
Donor type
Matched related 1.00 0.91 1.00 0.9
Other 1.06 (0.37–3.06) 0.93 (0.33–2.66)
Conditioning
Myeloablative 1.00 0.47 1.00 0.41
Reduced intensity 0.68 (0.23–1.96) 0.64 (0.23–1.83)
Prophylaxis against GvHD
CsA + MTX 1.00 0.32 1.00 0.75
CsA + MMF 2.34 (0.51–10.78) 1.27 (0.29–5.67)
ATG
No ATG 1.00 0.99 1.00 0.89
ATG ≤ 7.5 mg 1.02 (0.33–3.12) 1.11 (0.37–3.35)
ATG > 7.5 mg 1.12 (0.14–8.97) 0.65 (0.08–5.19)
HBV-immune/exposed donor
No 1.00 0.039 1.00 0.045 1.00 0.068 1.00 0.041
Yes 0.12 (0.02–0.89) 0.12 (0.02–0.96) 0.15 (0.02–1.15) 0.11 (0.01–0.92)
Prophylaxis with lamivudine
No 1.00 0.58 1.00 0.74
Yes 1.79 (0.22–14.32) 1.43 (0.18–11.5)
Length of cyclosporine administration
(for 1-month increase)
1.01 (0.99–1.03) 0.38 1.03 (1.01–1.04) 0.001 1.03 (1.01–1.04) <0.001
Time-dependent characteristics Cumulative incidence (landmark at 6 months)
Acute GvHD
No 1.00 0.83 1.00 0.77
Grade I 1.12 (0.24–5.25) 1.08 (0.24–4.96)
Grade ≥ II 0.83 (0.15–4.53) 0.70 (0.13–3.87)
Chronic GvHD
No 1.00 0.82 1.00 0.63
Limited 1.58 (0.34–7.37) 1.20 (0.37–3.88)
Extensive 1.29 (0.21–7.74) 0.56 (0.10–3.05)
Relapse (yes vs. no) 1.62 (0.45–5.85) 0.46 1.70 (0.18–15.9) 0.64
Rituximab
No 1.00 0.044 1.00 0.11 1.00 <0.001 1.00 <0.001
Low dose for PTLD-prophylaxis NC NC NC NC
Therapeutic dose 4.50 (1.21–16.8) 2.91 (0.77–10.97) 1.64 (0.38–7.15) 1.17 (0.32–4.31)
High dose (>1 mg/kg) steroid
treatment (yes vs. no)
1.33 (0.17–10.76) 0.79 1.70 (0.18–15.92) 0.64
ATG, antithymocyte globulin; CsA, cyclosporine A; GvHD, graft vs. host disease; HR, hazard ratio; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MTX,
methotrexate; NC, no cases; PTLD, post-transplant lymphoproliferative disease; SHR, sub-hazard ratios.
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Discussion
In this study, a cohort of 764 allogeneic HSCT recipients that
included 137 HBsAg/HBcAb+ patients was analysed. The
main ﬁndings are: (i) being HBcAb+ did not negatively affect
outcome, such as overall survival, NRM or development of
GvHD; (ii) the incidence of HBV reactivation was 10.2% and it
occurred at a median of 1 year and 7 months after HSCT; (iii)
donor’s immunity was independently associated with a
decreased risk of HBV reactivation; (iv) length of administra-
tion of cyclosporine and treatment with rituximab, but not
low-dose rituximab given as PTLD-prophylaxis, were associ-
ated with a signiﬁcantly increased probability of HBV reacti-
vation.
The overall prevalence of HBV exposure was 19%, similar
to that reported for Italian HSCT recipients (24–26%) [9,12].
The possibility that previous exposure to HBV might negatively
inﬂuence the outcome of HSCT was assessed. Similarly to
what was reported in a smaller cohort of 76 HBsAg/HBcAb+
patients, there was no difference in overall survival, NRM and
incidence of GvHD, even after adjusting for factors associated
with each of these variables [23].
In previous studies that included more than 25 HBsAg/
HBcAb+ patients, the median reactivation incidence was 12%,
varying from 11% to 29% [3,4,8–10,12,23]. In this cohort the
reactivation rate was 10% and the high rate of HBV-immune/
exposed donors might explain the slightly lower incidence of
reactivation. As in other cohorts, the reactivation occurred
late after HSCT (19 months) [4,7,9,10,12,23,24]. Notably, the
longer the time interval from HSCT, the higher the reactiva-
tion rate, as in this study 26% of patients who were alive more
than 7 years after HSCT experienced HBV reactivation. Thus,
lifelong surveillance is mandatory to diagnose all cases of
reactivation.
Identifying risk factors for complications that present late
after HSCT is challenging, because the analyses must adjust for
numerous baseline and post-transplant variables that inﬂuence
signiﬁcantly survival (competing risks) and, as a consequence,
the probability of developing such a late event as HBV
reactivation. Therefore, two different analyses of risk factors
were performed. Analyses of cause-speciﬁc hazard factors
identiﬁed variables that had a direct impact on HBV reactiva-
tion, whereas analyses of competing risks described the
probability of developing HBV reactivation, while taking into
consideration other factors that inﬂuenced survival.
To our knowledge, this study is the ﬁrst to consistently
demonstrate that transplant from an HBV-immune or
exposed donor is independently and signiﬁcantly associated
with protection against HBV reactivation in HBsAg/HBcAb+
patients, as no other study reported a statistically signiﬁcant
protective role of donor’s immunity [3,5,12]. In the setting of
allogeneic HSCT, transfer of immunity from donors with HBV
infection was associated in recipients with both resolution of
a chronic hepatitis [25] and maintenance of the immunity
[26]. While donor’s previous natural exposure seemed
necessary for resolution of recipient’s chronic infection
[25], this study demonstrated that vaccination of the donor
could be sufﬁcient to prevent HBV reactivation in HBsAg/
HBcAb+ recipients. Therefore, vaccination of donors could
signiﬁcantly reduce the burden of HBV reactivation in
HBcAb+ patients.
As far as immunosuppressive therapy is concerned, an
increased risk was associated with cyclosporine or rituximab
treatment. The role of treatment with cyclosporine and
steroids has also been noted in another study, but, unlike in
this cohort, the difference in the length of immunosuppres-
sive treatment between the patients with and without
reactivation was not corrected for the reported difference
in the length of follow-up [12]. Rituximab has been
associated with a high rate of HBV reactivation in different
settings [27]. This study conﬁrms that even in patients with
a severe, complex, long-lasting immunodeﬁciency, treatment
with rituximab was an independent risk factor for reactiva-
tion.
Despite the lack of studies on lamivudine prophylaxis in
HBsAg/HBcAb+ HSCT recipients, based on the data from
HBsAg+ patients, since 2007 and 2009 the international
guidelines have recommended lamivudine also for HBcAb+
patients [28,29]. Unfortunately, no data can be provided on
the efﬁcacy of such a strategy as routine prophylaxis with
lamivudine was administered only to patients undergoing
transplantation in the last 18 months of the study.
FIG. 1. Inﬂuence of donor immunity on the risk of HBV reactivation.
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Several limitations of this study should be acknowledged.
Firstly, due to the retrospective design and the 10-year-long
observation period, serological testing in asymptomatic
patients was not performed at regular intervals and different
HBV-DNA assays were used. Therefore, some cases of
reactivation might have remained undetected and, conse-
quently, the reactivation rate underestimated. Secondly, the
population at risk of reactivation was deﬁned only on the basis
of a serological proﬁle compatible with a past HBV infection,
although isolated HBcAb-positivity is not synonymous with an
occult infection, and it does not distinguish between a
resolved, an occult and a replicative HBsAg-negative infection
[1,30]. The diagnosis of an occult infection is established only
on the basis of HBV-DNA-positive liver biopsy, which is rarely
feasible in this setting [30]. Additionally, false isolated HBcAb
positivity has been reported [31]. Thus, the real incidence of
HBV reactivation might be higher in patients with a seropos-
itive occult HBV infection. On the other hand, up to 20% of
patients with an occult HBV infection might have all serological
markers of HBV infection negative [30]. Therefore, without a
liver biopsy they are not considered to be at risk of HBV
reactivation. Despite all these limitations, all the available data
on the risk of HBV reactivation in HBsAg-negative patients
with haematological malignancies come from studies in
HBcAb+ subjects, for whom different terms are used, including
a resolved, past or occult HBV infection [32,33]. Thirdly,
donors’ HBsAb titres were not routinely available, so the
association between the level of donor’s antibody titre and the
risk of reactivation could not be assessed. Finally, this is a
retrospective and single-centre study, and the limited number
of reactivation cases and the multiplicity of risk factors
considered in the model reduced the power of risk analysis.
Nevertheless, this is the largest, to our knowledge, cohort of
HBsAg/HBcAb+ allogeneic HSCT recipients who were for
years closely followed by a single transplant centre.
In conclusion, HBV reactivation is a frequent and late
complication in HBsAg/HBcAb+ allogeneic HSCT recipients.
Thus, life-long HBV monitoring is mandatory. The risk of
reactivation depends on speciﬁc immunosuppressive treat-
ments, which usually cannot be reduced, as they are essential
for the control of the underlying disease or GvHD. On the
contrary, immunization of the donor should be pursued as it is
feasible and could signiﬁcantly reduce the risk of HBV
reactivation.
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Appendix 1: Clinical characteristics of 14 patients with HBV reactivation.
No.
Age
(years),
sex
Recipient
HBsAb
(mIU/mL)
Time from
HSCT to
reactivation
(months)
At reactivation
Antiviral
therapy
At last follow-up
ALT
(U/L) HBsAg HBeAg
HBV-DNA
(Log IU/mL)a HBsAg HBeAg
HBV
DNA
(Log
IU/mL)
Months
after
reactivation
Follow-up
(months),
status
1. 45 M >10 25 17 + ND ND LAM  ND  120 145, A
2. 30 M 1000 9 68 + + +b ADF ND ND 5.2 58 67, lost
3. 42 M 210 73 130 + + 7.2 ETV >
ETV+TDF
+ + 0.2 60 133, A
4. 37 F 1000 13 351 + + 6.7 LAM + ND +b 1 14, D
5. 56 M 5 28 85 + + 7.3 LAM + ND ND 76 103, lost
6. 16 M 148 15 736 + + 5.3  ND ND  26 41, lost
7. 46 F 999 42 53 + ND 7.8 LAM >
LAM+TDF
+ + 1.5 66 84, A
8. 50 M 378 15 13 + + ND LAM + + 2.8 24 39, D
9. 19 M 126 36 390 + + 7.3 ETV +   59 96, A
10. 36 M 1000 77 39 + + 8.0 ETV + + 4.2 18 95, A
11. 37 F 664 21 150 + + 6.5 LAM    73 95, A
12. 55 M <10 10 50 + + 7.3 LAM + + ND 3 12, D
13. 61 M 242 13 43 +  ND LAM + ND  61 73, A
14. 54 M 1 16 1141 + + 6.8 ETV    30 47, A
+, positive; , negative; A, alive; ADF, adefovir; ALT, alanine aminotransferase; D, dead; ETV, entecavir; F, female; HSCT, haematopoietic stem cell transplant; LAM, lamivudine; M,
male; ND, no data; TDF, tenofovir disoproxil fumarate.
aHBV-DNA was not tested at reactivation in patients 1, 8 and 13.
bQualitative assessment of HBV DNA; quantitative assay not performed.
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